Skip to main content

PAH

2
Pipeline Programs
3
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Medpace
MedpaceCINCINNATI, OH
2 programs
2
75mg CXA-10Phase 21 trial
CXA-10Phase 21 trial
Active Trials
NCT03449524Terminated69Est. Aug 2020
NCT04053543Terminated33Est. Aug 2020
United Therapeutics
United TherapeuticsMD - Silver Spring
5 programs
TransCon PEG treprostinilPHASE_11 trial
oral treprostinilPHASE_21 trial
RalinepagPHASE_31 trial
RalinepagPHASE_31 trial
RalinepagPHASE_31 trial
Active Trials
NCT02149095Withdrawn0
NCT02276872Completed32Est. Jul 2017
NCT03683186Enrolling By Invitation1,000Est. Dec 2026
+2 more trials
Philips
PhilipsNetherlands - Amsterdam
1 program
75mg CXA-10PHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
United TherapeuticsRalinepag
United TherapeuticsRalinepag
United TherapeuticsRalinepag
MedpaceCXA-10
Medpace75mg CXA-10
United Therapeuticsoral treprostinil
United TherapeuticsTransCon PEG treprostinil

Clinical Trials (7)

Total enrollment: 1,831 patients across 7 trials

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

Start: Jan 2021Est. completion: Apr 202310 patients
Phase 3Terminated

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Start: Sep 2019Est. completion: Dec 20261,000 patients
Phase 3Enrolling By Invitation

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Start: Jan 2019Est. completion: Dec 2025687 patients
Phase 3Completed

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

Start: Aug 2019Est. completion: Aug 202033 patients
Phase 2Terminated

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

Start: Aug 2018Est. completion: Aug 202069 patients
Phase 2Terminated

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Start: Dec 2014Est. completion: Jul 201732 patients
Phase 2Completed
NCT02149095United TherapeuticsTransCon PEG treprostinil

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Start: Jul 20140
Phase 1Withdrawn

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.